Skip to main content
SpringerLink
Log in

In vitro activity of isavuconazole against clinically isolated yeasts from Chile

  • Clinical Microbiology - Short Communication
  • Published:
Brazilian Journal of Microbiology Aims and scope Submit manuscript

Abstract

Isavuconazole is the last antifungal agent approved by the FDA and available for treatment of fungal infections. In the present study, the in vitro activity of isavuconazole against several yeasts was investigated. Two hundred forty-six isolates were included: 64 Candida albicans, 53 Candida parapsilosis sensu stricto, 48 Cryptococcus neoformans species complex, 27 C. glabrata sensu stricto, 17 C. lusitaniae, 17 C. tropicalis, 5 C. orthopsilosis, 4 C. krusei, 3 C. guilliermondii sensu stricto, 3 C. pelliculosa, 2 C. dubliniensis, 1 C. auris, 1 C. fermentati and 1 Trichosporon asahii. All isolates were recovered from clinical isolates from Chile, being 221 from hemoculture, 22 from cerebrospinal fluid, 1 pleural fluid, and 1 from tissue culture. The minimal inhibitory concentrations (MICs) and minimal fungicidal concentrations (MFCs) of isavuconazole were determined. Isavuconazole demonstrated good in vitro activity against all species tested. MIC90 values and MFC ranges of isavuconazole for Candida albicans were 0.03 mg/L and 0.03– > 16 mg/L respectively. Non–Candida albicans species isolates were inhibited by ≤ 1 mg/L, with MFC ranges from < 0.03– > 16 mg/L. Also, isavuconazole was active against the non-Candida yeasts, being inhibited with MIC values ≤ 0.06 mg/L. Isavuconazole has exhibited potent in vitro activity against clinical isolates of Candida spp., Cryptococcus neoformans species complex, and other clinical yeast in Chile. Despite the results obtained in the present work, additional clinical studies are necessary to verify the level of efficacy of this azole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Miceli MH, Kauffman CA (2015) Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 61(10):1558–1565

    Article  CAS  Google Scholar 

  2. Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH (2016) Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag 12:1197–1206

    Article  CAS  Google Scholar 

  3. Aigner M, Chandorkar P, Mutschlechner W, Lass-Flörl C (2016) Isavuconazole: an orphan drug for treating invasive candidiasis. Expert Opinion on Orphan Drugs 4(3):333–342

    Article  CAS  Google Scholar 

  4. Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P (2019) Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial. Clin Infect Dis 68(12):1981–1989

    Article  CAS  Google Scholar 

  5. Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M (2015) A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother 59(3):1671–1679

    Article  CAS  Google Scholar 

  6. Astvad KM, Hare RK, Arendrup MC (2017) Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clin Microbiol Infect 23(11):882–887

    Article  CAS  Google Scholar 

  7. Clinical and Laboratory Standards Institute (2017) Reference method for broth dilution antifungal susceptibility testing of yeasts. 4th ed. CLSI standard M27

  8. Clinical and Laboratory Standards Institute (2017) Performance standards for antifungal susceptibility testing of yeasts, 1st ed. CLSI document M60

  9. Clinical and Laboratory Standards Institute (2016) Epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M59

  10. Desnos-Ollivier M, Bretagne S, Boullié A, Gautier C, Dromer F, Lortholary O (2019) French mycoses study group. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015–2017). Clin Microbiol Infect 25(5):634–6e1

    Article  CAS  Google Scholar 

  11. Espinel-Ingroff A (1998) Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991(L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36(10):2950–2956

    Article  CAS  Google Scholar 

  12. Duarte EA, Denning DW (2017 Jun 1) Serious fungal infections in Chile. Eur J Clin Microbiol Infect Dis 36(6):983–986

    Article  Google Scholar 

  13. Instituto de Salud Pública de Chile (2017) Resultado de vigilancia del laboratorio Candidemia 2015–2016. Bol. 7(1)

  14. Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC (2013) Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother 57(11):5426–5431

    Article  CAS  Google Scholar 

  15. Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A (2017) Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother 61(6):e00485–e00417

    Article  Google Scholar 

  16. Parra-Giraldo CM, Valderrama SL, Cortes-Fraile G, Garzón JR, Ariza BE, Morio F, Linares-Linares MY, Ceballos-Garzón A, de la Hoz A, Hernandez C, Alvarez-Moreno C (2018) First report of sporadic cases of Candida auris in Colombia. Int J Infect Dis 69:63–67

    Article  Google Scholar 

  17. Osei SJ (2018 Aug) Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen. 7(4):e00578

    Article  Google Scholar 

  18. Thompson GR, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF (2009) Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 53(1):309–311

    Article  CAS  Google Scholar 

  19. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, Thompson GR, Turnidge J (2015) Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 59(1):666–668

    Article  CAS  Google Scholar 

  20. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, ESCMID EFISG study group and ECMM (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 20:76–98

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mycology Unit, Microbiology and Mycology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile

    Eduardo Álvarez Duarte

  2. Mycology Laboratory, Biomedical Department, Public Health Institute of Chile, Santiago, Chile

    Valentina Salas

Authors
  1. Eduardo Álvarez Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Salas
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors contributed equally to this manuscript.

Corresponding author

Correspondence to Eduardo Álvarez Duarte.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Responsible Editor: Rosana Puccia

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(XLSX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Álvarez Duarte, E., Salas, V. In vitro activity of isavuconazole against clinically isolated yeasts from Chile. Braz J Microbiol 51, 1801–1805 (2020). https://doi.org/10.1007/s42770-020-00333-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42770-020-00333-x

Keywords

Search

Navigation